P&T COMMITTEE MEETING

Agenda April 2, 2019
1:00 p.m. – 5:00 p.m.

303 E. 17th Ave, 11th Floor Conference Rooms (11ABC), Denver, CO 80203

□ Committee Member Introductions

Unfinished Business and General Orders

• Approval of minutes from January 8, 2019 P&T meeting
• Update on Atypical Antipsychotics
• Update on Calcitonin Gene-Related Peptide (CGRP) Inhibitors
• Update on Growth Hormones
• Update on Insulins
• Update on Intranasal Corticosteroids
• Update on Lipotropics and Bile Salts
• Update on Multiple Sclerosis Agents
• Update on Neurocognitive Disorder Agents
• Update on Anti-Parkinson Agents
• Update on Ophthalmic Glaucoma Agents
• Update on Topical Steroids
• Update on Mass review drug classes:
  o Leukotriene Modifiers
  o Ophthalmic Allergy
  o Sedative Hypnotics
  o Statin & Statin Combinations

New Business

1. Updates from the Prior Authorization Call Center
2. Clinical Materials
Drug Classes Up for Review:

- Review of Acne Agents
  - Oral Isotretinoin, Topical
  - Tetracyclines
- Review of Rosacea Agents, Topical
- Review of Non-Opioid Analgesics
- Review of Opioids – Short-Acting
- Review of Opioids – Long-Acting
- Review of Benign Prostatic Hypertrophy (BPH) Agents
- Review of Phosphate Binders
- Review of Respiratory Inhalants
  - Inhaled Anticholinergics & Anticholinergic Combinations
  - Inhaled Beta2 Agonists (short-acting)
  - Inhaled Beta2 Agonists (long-acting)
  - Inhaled Corticosteroids and Combinations
- Review of Androgenic Agents

Mass review drug classes:
  - Review of Angiotensin modulators and Angiotensin modulator combinations
    - ACEis, ACEi Combos
    - ARBs, ARB Combos
    - Renin Inhibitors & Combos
      - Antihistamines, Newer Generation
      - Skeletal Muscle Relaxants
      - Topical Immunomodulators

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advance notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.
- Please contact Brittany Schock, PDL Pharmacist, at 303-866-6371 or by email at brittany.schock@state.co.us to give advance notice to present at the meeting. Written public comments can be submitted to Jessica Czechowski, Clinical Account Manager jlczechowski@magellanhealth.com (cc: Brittany Schock) and will be distributed to all present P&T Committee Members. Please provide public comments by March 28th, 2019 for dissemination to the P&T Committee.

Upcoming Meeting Date: Tuesday, July 9, 2019; 1:00 p.m. – 5:00 p.m.